Mythic Therapeutics develops FateControl™ technology to enhance the efficacy of antibody-drug conjugates (ADCs) by increasing their uptake in cancer cells while preventing payload release in healthy tissues. This approach significantly improves treatment outcomes for a wider range of cancer types by reducing toxicity and side effects associated with traditional chemotherapy delivery methods.
Funding
$156.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VGFounders
Product
Problem
Traditional antibody-drug conjugates (ADCs) often exhibit limited efficacy and significant toxicity because a large percentage of the drug payload is released in healthy tissues instead of being delivered specifically to cancer cells. This off-target release reduces the therapeutic window and limits the applicability of ADCs across a broader range of cancer types.
Solution
Mythic Therapeutics is developing FateControl™ technology, a novel approach to enhance the efficacy and safety of antibody-drug conjugates (ADCs). FateControl™ increases the uptake of ADCs specifically in cancerous cells while simultaneously preventing the premature release of the cytotoxic payload in healthy tissues. By improving targeted delivery and reducing off-target effects, FateControl™ aims to expand the therapeutic window of ADCs, leading to better treatment outcomes for a wider range of cancer targets and patient populations.
Target Audience
The primary target audience includes pharmaceutical companies developing antibody-drug conjugates and oncologists seeking more effective and less toxic cancer therapies.
Features
- FateControl™ technology enhances ADC uptake in cancerous cells.
- FateControl™ technology prevents payload release in healthy tissues.
- Aims to increase efficacy for a wide range of targets and cancer types.
- Designed to reduce side-effects or toxicity.